P-187 - RISK ASSESSMENT FOR POTENTIAL DRUG-DRUG INTERACTIONS (DDI) FOR BINTRAFUSP ALFA: A TOTALITY OF EVIDENCE APPROACH INFORMED BY EVALUATION OF CYP3A BIOMARKER MODULATION, CYTOKINE PROFILES, AND TGF-β TRANSCRIPTOMICS.
Y. Vugmeyster1, G. Locke1, C. Helwig2, P. Rolfe1, J. Dong1, K. Venkatakrishnan1; 1EMD Serono, Billerica, MA, USA, 2Merck KGaA, Darmstadt, Germany.
.png)